Loading patent…
AssigneeGilead Sciences, Inc.
InventorsJiani Li, Xinan Liu, Azure T. Makadzange, Stephen R. Martin, Sarah Schmidt, Hesham Shehata, Felix Stemeseder, Evguenia Svarovskaia, Archana V. Boopathy
Estimating the term…
Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.
1-32. (canceled)
A fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs:
34-45. (canceled)
47-51. (canceled)
55-62. (canceled)
64-138. (canceled)
140-144. (canceled)
146-160. (canceled)
(canceled)
165-181. (canceled)
183-212. (canceled)
The immunogenic composition of, formulated as a liquid, a suspension or an emulsion.
The immunogenic composition of, wherein the composition is lyophilized.
217-311. (canceled)
313-504. (canceled)
Dependencies are inferred from the claim text.